Sotagliflozin — potenzielle Option zur Therapie des Typ-1-Diabetes
Crossref DOI link: https://doi.org/10.1007/s15006-018-0438-8
Published Online: 2018-04-16
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Red,
Text and Data Mining valid from 2018-04-01
Article History
First Online: 16 April 2018